EP1797427A4 - Verfahren zur identifizierung neuer arzneimittel-leads und neuer therapeutischer verwendungen für bekannte arzneimittel - Google Patents

Verfahren zur identifizierung neuer arzneimittel-leads und neuer therapeutischer verwendungen für bekannte arzneimittel

Info

Publication number
EP1797427A4
EP1797427A4 EP05813818A EP05813818A EP1797427A4 EP 1797427 A4 EP1797427 A4 EP 1797427A4 EP 05813818 A EP05813818 A EP 05813818A EP 05813818 A EP05813818 A EP 05813818A EP 1797427 A4 EP1797427 A4 EP 1797427A4
Authority
EP
European Patent Office
Prior art keywords
methods
therapeutic uses
known drugs
drug leads
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05813818A
Other languages
English (en)
French (fr)
Other versions
EP1797427A2 (de
Inventor
John K Westwick
Marnie L Macdonald
Helen Yu
Stephen Owens
Stephen W Michnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Odyssey Pharmaceuticals Inc
Original Assignee
Odyssey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odyssey Pharmaceuticals Inc filed Critical Odyssey Pharmaceuticals Inc
Priority claimed from PCT/US2005/033984 external-priority patent/WO2006036737A2/en
Publication of EP1797427A2 publication Critical patent/EP1797427A2/de
Publication of EP1797427A4 publication Critical patent/EP1797427A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP05813818A 2004-09-22 2005-09-22 Verfahren zur identifizierung neuer arzneimittel-leads und neuer therapeutischer verwendungen für bekannte arzneimittel Withdrawn EP1797427A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61171504P 2004-09-22 2004-09-22
PCT/US2005/033984 WO2006036737A2 (en) 2004-09-22 2005-09-22 Methods for identifying new drug leads and new therapeutic uses for known drugs

Publications (2)

Publication Number Publication Date
EP1797427A2 EP1797427A2 (de) 2007-06-20
EP1797427A4 true EP1797427A4 (de) 2009-04-08

Family

ID=38039105

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05813818A Withdrawn EP1797427A4 (de) 2004-09-22 2005-09-22 Verfahren zur identifizierung neuer arzneimittel-leads und neuer therapeutischer verwendungen für bekannte arzneimittel

Country Status (1)

Country Link
EP (1) EP1797427A4 (de)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034146A1 (en) * 1996-03-12 1997-09-18 The General Hospital Corporation Inhibiting protein interactions
US5736337A (en) * 1993-06-11 1998-04-07 The General Hospital Corporation Inhibiting protein interactions
WO1998034120A1 (en) * 1997-01-31 1998-08-06 Universite De Montreal Protein fragment complementation assays to detect biomolecular interactions
WO1999024603A1 (en) * 1997-11-06 1999-05-20 Fred Hutchinson Cancer Research Center Method for identifying drug targets
WO2000033917A1 (de) * 1998-12-04 2000-06-15 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten
WO2003063866A1 (en) * 2002-02-01 2003-08-07 The University Of Birmingham Agents which interact with a serotonin transporter for the treatment of cancer
WO2003070249A1 (de) * 2002-02-19 2003-08-28 Nowak Goetz Kombination von trapidil mit serotoninantagonisten wie cyproheptadin oder pizotifen zur hemmung der angiogenese
WO2004009136A2 (en) * 2002-07-22 2004-01-29 Psimei Pharmaceuticals Plc Conjugates of n-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds
CN1486694A (zh) * 2003-08-07 2004-04-07 秦吉兴 一种治疗癌症的药物
WO2004061422A2 (en) * 2002-12-31 2004-07-22 Rodi Pharma, Inc. Bindingzyme arrays and high-throughput proteomic methods
US20040161787A1 (en) * 1997-01-31 2004-08-19 Odyssey Thera, Inc. Protein fragment complementation assays for high-throughput and high-content screening
WO2005100588A2 (en) * 2004-04-12 2005-10-27 Odyssey Thera, Inc. Protein-protein interactions for pharmacological profiling

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736337A (en) * 1993-06-11 1998-04-07 The General Hospital Corporation Inhibiting protein interactions
WO1997034146A1 (en) * 1996-03-12 1997-09-18 The General Hospital Corporation Inhibiting protein interactions
WO1998034120A1 (en) * 1997-01-31 1998-08-06 Universite De Montreal Protein fragment complementation assays to detect biomolecular interactions
US20040161787A1 (en) * 1997-01-31 2004-08-19 Odyssey Thera, Inc. Protein fragment complementation assays for high-throughput and high-content screening
WO1999024603A1 (en) * 1997-11-06 1999-05-20 Fred Hutchinson Cancer Research Center Method for identifying drug targets
WO2000033917A1 (de) * 1998-12-04 2000-06-15 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten
WO2003063866A1 (en) * 2002-02-01 2003-08-07 The University Of Birmingham Agents which interact with a serotonin transporter for the treatment of cancer
WO2003070249A1 (de) * 2002-02-19 2003-08-28 Nowak Goetz Kombination von trapidil mit serotoninantagonisten wie cyproheptadin oder pizotifen zur hemmung der angiogenese
WO2004009136A2 (en) * 2002-07-22 2004-01-29 Psimei Pharmaceuticals Plc Conjugates of n-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds
WO2004061422A2 (en) * 2002-12-31 2004-07-22 Rodi Pharma, Inc. Bindingzyme arrays and high-throughput proteomic methods
CN1486694A (zh) * 2003-08-07 2004-04-07 秦吉兴 一种治疗癌症的药物
WO2005100588A2 (en) * 2004-04-12 2005-10-27 Odyssey Thera, Inc. Protein-protein interactions for pharmacological profiling

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200442, Derwent World Patents Index; AN 2004-441504, XP002515694 *
HARTWELL L H ET AL: "INTEGRATING GENETIC APPROACHES INTO THE DISCOVERY OF ANTICANCER DRUGS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, WASHINGTON, DC, vol. 278, 7 November 1997 (1997-11-07), pages 1064 - 1068, XP002916842, ISSN: 0036-8075 *
HUGHES T R ET AL: "Functional discovery via a compendium of expression profiles", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 102, no. 1, 7 July 2000 (2000-07-07), pages 109 - 126, XP002225641, ISSN: 0092-8674 *
KUNKEL E J ET AL: "RAPID STRUCTURE-ACTIVITY AND SELECTIVITY ANALYSIS OF KINASE INHIBITORS BY BIOMAP ANALYSIS IN COMPLEX HUMAN PRIMARY CELL-BASED MODELS", ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, US, vol. 2, no. 4, 1 August 2004 (2004-08-01), pages 431 - 441, XP009053543, ISSN: 1540-658X *
MARTON M J ET AL: "Drug target validation and identification of secondary drug target effects using DNA microarrays", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 4, no. 11, 1 November 1998 (1998-11-01), pages 1293 - 1301, XP002168523, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
EP1797427A2 (de) 2007-06-20

Similar Documents

Publication Publication Date Title
EP1824410A4 (de) Systeme und verfahren zur intraoralen arzneimittelabgabe
IL174894A0 (en) Transdermal drug delivery device
EP1648327A4 (de) Orale vorrichtungen und verfahren für die kontrollierte arzneimittelabgabe
EP1802258A4 (de) Biosynchrone transdermale arzneiabgabe
HUE053781T2 (hu) Rendszer és módszer gyógyszeradagolási információk meghatározására
EP1829518A4 (de) Medikamentenmixer zur verabreichung von arzneimitteln
EP1510207A4 (de) Therapeutisches arzneimittel gegen diabetes
EP1790375A4 (de) Transdermale arzneimittelverabreichungsvorrichtung mit mikronadel
EP1804767A4 (de) Biokompatibles arzneiabgabegerät und verfahren
DE60329729D1 (de) Implantierbare Vorrichtung zur Arzneimittelverabreichung
EP1903936A4 (de) Arzneimittelübereinstimmungssystem und dazugehörige verfahren
IL179140A0 (en) Antibody drug conjuates and methods
AU2003221770A8 (en) Controlled release transdermal drug delivery
PL1957073T3 (pl) Substancja lecznicza
IL180284A0 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
GB0418328D0 (en) Cancer methods and medicaments
IL180770A0 (en) Oxopiperidine derivatives, preparation and therapeutic use thereof
HK1095036A1 (en) Virus therapeutic drug
EP1706129A4 (de) Medikamententherapie für zöliakie
IL180797A0 (en) Amino-tropane derivatives, preparation thereof and therapeutic use thereof
EP1838288A4 (de) Therapeutische stoffe und verfahren
PL1858496T3 (pl) Poprzezskórny układ terapeutyczny do aplikowania środków przeciwbólowych
GB0810016D0 (en) Method and system for transdermal drug delivery
EP1782821A4 (de) Arzneimittel und verfahren zur verbesserung der gehirnfunktion
IL172250A0 (en) Improved pharmaceutical drug candidates and methods for preparation thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070327

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/00 20060101ALI20070717BHEP

Ipc: C12Q 1/00 20060101AFI20070717BHEP

Ipc: G01N 33/53 20060101ALI20070717BHEP

Ipc: C12P 21/00 20060101ALI20070717BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090309

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20090227BHEP

Ipc: C12P 21/00 20060101ALI20090227BHEP

Ipc: C12Q 1/00 20060101AFI20070717BHEP

Ipc: C12N 5/00 20060101ALI20090227BHEP

Ipc: G01N 33/53 20060101ALI20090227BHEP

17Q First examination report despatched

Effective date: 20090707

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130403